Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: Its Application to Clinical Practice

pp 305-312

Authors

  • Christian Hotch Chair of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Institute of Physiopathology and Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, University of Buenos Aires.
  • Marcos A. Mayer Chair of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Institute of Physiopathology and Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, University of Buenos Aires.
  • Javier A. W. Opezzo Chair of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Institute of Physiopathology and Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, University of Buenos Aires.
  • Facundo M. Bertera Chair of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires.
  • Carlos A. Taira Chair of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Institute of Physiopathology and Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, University of Buenos Aires.

DOI:

https://doi.org/10.7775/2yz8za46

Keywords:

Antihypertensive drugs, Pharmacokinetic-pharmacodynamic modeling, Clinical practice, Dose optimization

Abstract

Knowledge of pharmacokinetic-pharmacodynamic (PK/PD) properties of antihypertensive drugs may optimize drug therapy of hypertension. PK/PD modeling in clinical research could contribute in drug development and clinical practice in several aspects, including an evaluation of the efficacy and safety of antihypertensive agents, enhancement of information during the development process, identification of factors that contribute to drug response variability, by allowing a rapid identification of poor or non responders and by helping to determine optimal antihypertensive drug and dose requirements in each hypertensive patient. There are some limitations in PK/PD modeling of antihypertensive drugs in the clinical setting, including application of inadequate pharmacodynamic models and the inability to study large doses of antihypertensive drugs in order to determine the complete pharmacodynamic range of their antihypertensive effect. The aim of the present review is to describe the current knowledge of PK/PD modeling of antihypertensive drugs in basic and clinical research and its future applications.

Downloads

Published

2026-01-06

Issue

Argent J Cardiol 2008 Vol. 76 Issue 4

Section

REVIEW ARTICLES

License

Copyright (c) 2026 Argentine Journal of Cardiology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

1 2 > >>